Why is "Gleevec" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-06-24 02:00:50
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Gleevec entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-06-24 and was most recently seen on 2026-06-24.
Wikipedia Overview
Imatinib, sold under the brand names Gleevec and Glivec (both marketed worldwide by Novartis) among others, is an oral targeted therapy medication used to treat cancer. Imatinib is a small molecule inhibitor targeting multiple tyrosine kinases such as CSF1R, ABL, c-KIT, FLT3, and PDGFR-β. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome–positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis, and myelodysplastic syndrome.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
How a pill approved 25 years ago transformed cancer treatment - NPR
-
From death sentence to manageable condition: 25 years of Gleevec - OHSU News
-
Durable Gleevec Benefit Doubles Survival in Advanced GIST - Cure Today
-
Revolutionary cancer-fighting drug developed in Oregon marks 25-year milestone - KGW
-
Leukemia May Build Resistance to Drug - ABC News - Breaking News, Latest News and Videos
-
Inside the Discovery That Changed CML Treatment Forever: Jorge Cortes, MD - AJMC
-
Essential Insights on GIST and Gleevec for Patients - Cure Today
-
This man was given three years to live … in 1998. He’s still here : Short Wave - NPR
-
Charting the Evolution of TKIs and Finding the Next Breakthrough in CML - CancerNetwork
-
AACR 2026: David Parkinson and the Arc of Modern Cancer Therapy - Inside Precision Medicine
-
Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal Stromal Tumors - National Cancer Institute (.gov)
-
Gleevec: How it works and how long it takes to work - Medical News Today
-
Gleevec Associated With Long-Term Effectiveness in Treating GIST - Cure Today
-
As Milestone Nears, an Early Investigator Reflects on Lessons of Imatinib - AJMC
-
Stopping TKI Treatment Is Safe, Improves Quality of Life for Some with CML - National Cancer Institute (.gov)
-
Top GI News From September: GIST, Pancreatic and Colorectal Cancers - Cure Today
-
New Treatment Combo Shows Benefit for Patients with GIST - Cure Today
-
Bezuclastinib Submitted to FDA for Patients With Previously Treated GIST - Cure Today
-
A New Option Without Traditional Chemotherapy for Ph+ ALL - Cure Today
-
How Targeted Therapies Are Transforming Chronic Myeloid Leukemia Care - Cure Today
-
8 Imatinib Side Effects You Should Know About - GoodRx
-
The Curious Case Of Gleevec Pricing - Forbes
-
The Immaculate Conception of Gleevec, As Told by Brian Druker - Genetic Engineering and Biotechnology News
-
Gleevec Interruption in GIST Associated with Resistance, Recurrence, Death - Cure Today
-
Gleevec Response in GIST May Be Linked to Mutational Profile - Cure Today
-
Recapping A Quarter Decade of Chronic Myeloid Leukemia Therapy - CancerNetwork
-
Side Effects Associated With Gleevec for GIST - Cure Today
-
How a CML clinical trial and Gleevec saved my life - UT MD Anderson
-
New England Journal of Medicine publishes long-term results of Gleevec® for patients with chronic myeloid leukemia - OHSU News
-
Novartis keeps the leukemia innovation coming with FDA approval for Gleevec follow-on Scemblix as Tasigna patent cliff nears - Fierce Pharma
-
7 Imatinib Interactions You Should Know About - GoodRx
-
Revolutionary drug that helps fight leukemia celebrates 25 years of saving lives - KGW
-
The Evolution of a Lifesaving Drug: A Scientist Reflects - Memorial Sloan Kettering Cancer Center
-
Emerging Clinical Trials Signal Progress in GIST Treatment - Cure Today
-
Longest Living Person to Receive Gleevec for Leukemia Shares Advice - Cure Today
-
FDA Approves Imatinib (Gleevec) for Pediatric ALL - CancerNetwork
-
Gleevec (Imatinib) Treatment Improves Survival in GISTs - news.cancerconnect.com
-
Machine Learning Predicts Gleevec Nonadherence in Patients With GIST - Cure Today
-
A Conversation with MSK’s Charles Sawyers: What’s Next for Precision Oncology - Memorial Sloan Kettering Cancer Center
-
First Patient Dosed in Trial of Ziftomenib for Advanced GIST - Cure Today
-
Gleevec cost 2026: Savings tips and more - Medical News Today
-
Novartis settles Gleevec lawsuit with Sun Pharma - Generics and Biosimilars Initiative
-
In 1998, a CML patient was out of options. Then she chanced into a treatment–Gleevec - The Cancer Letter
-
Modest Price Cut Expected For Generic Version Of Cancer Pill Gleevec : Shots - Health News - NPR
-
Novartis, Dana Farber, Oregon Health & Science University Wait 18 Years to Disclose NIH Funding in Key Gleevec Patent - Petrie-Flom Center
-
Gleevec: A 'Miracle Drug' for Some Patients With Chronic Myeloid Leukemia - Cure Today
-
The survivors: How an experimental treatment saved patients and changed medicine - STAT
-
Gleevec Turned the Clock on a Late-Stage Leukemia Diagnosis - Cure Today
-
Energetic dissection of Gleevec's selectivity toward human tyrosine kinases - Nature
-
Shorla gains FDA nod for first oral liquid version of Novartis' Gleevec - Fierce Pharma
-
ASCO: Novartis' Scemblix proves edge over predecessor Gleevec in newly diagnosed leukemia - Fierce Pharma
-
Iclusig Leads to Better Responses Than Gleevec in Leukemia Subset - Cure Today
-
Leukemia drug Gleevec, the brand name for imatinib, fends off blood cancer for a decade, study shows - CBS News
-
Photo: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment - Novartis
-
Combination of Gleevec® and Hydrea® Offers Promise for Glioblastoma Multiforme - news.cancerconnect.com
-
Novartis' Scemblix leaps into newly diagnosed leukemia—where winning over doctors may take time - Fierce Pharma
-
Scemblix May Outperform Standard Treatments for Chronic Myeloid Leukemia - Cure Today
-
New drug Gleevec dissolves stomach tumors - Harvard Gazette
-
Explaining why Gleevec is a specific and potent inhibitor of Abl kinase - PNAS
-
FDA Grants Imatinib (Gleevec) Full Approval for Adjuvant Treatment of GIST - CancerNetwork
-
Prominent UCLA Stem Cell Researcher Inducted into Cancer Research Academy - UCLA Health
-
FDA Approves First Oral Liquid Imatinib for Leukemia and Other Cancers - Targeted Oncology
-
Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia - The Cancer Letter
-
The Mel Mann Story: From Terminal Cancer to 30 Year Survivor - Oncodaily
-
Why Chemotherapy That Costs $70,000 in the U.S. Costs $2,500 in India - The Atlantic
-
Gleevec: Prototype or Outlier? - Science | AAAS
-
Old Novartis cancer flagship Gleevec heads to pharmacies as lower-cost generic - BioPharma Dive
-
Colombia Threatens to Override Novartis’s Patent on Gleevec - WSJ
-
GLEEVEC (imatinib) for Ph+ Chronic Myeloid Leukemia - Cancer Therapy Advisor
-
Novartis to maintain Gleevec exclusivity until early 2016 - BioPharma Dive
-
ASCO: Takeda's Iclusig shows potential to become standard of care in acute lymphoblastic leukemia subtype - Fierce Pharma
-
Novartis settles Gleevec lawsuit with Sun Pharma - Generics and Biosimilars Initiative
-
ASCO: Novartis eyes full nod for Gleevec follow-on Scemblix thanks to new leukemia data - Fierce Pharma
-
The Arrival of Generic Imatinib Into the U.S. Market: An Educational Event - The ASCO Post
-
Imatinib Remains Standard of Care in GIST With ‘a Long Way to Go’ - OncLive
-
This pill is helping cancer patients live for 10 years or longer - NBC News
-
Periorbital Oedema and epiphora as ocular side effects of imatinib Mesylate (Gleevec) - Eye - Nature
-
Mel Mann: Gleevec’s Anniversary - Oncodaily
-
Subcapsular Liver Hematoma in Metastatic GIST Complicating Imatinib (Gleevec) Therapy - ScienceDirect.com
-
1998: Gleevec - Willamette Week
-
This cancer pill might turn around the worst type of diabetes - NBC News
-
Colombia health ministry recommends compulsory license for Novartis’ Gleevec - BioPharma Dive
-
Unswayed by pushback, Colombia moves to 'unilaterally' set price for Novartis' Gleevec - Fierce Pharma
-
Imatinib (Gleevec) - Oncology Nurse Advisor
-
Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines - Nature
-
Iclusig Boosts MRD-Negative Complete Response in Ph-Positive ALL - Cure Today
-
Scemblix May Be a Better Option for Chronic Myeloid Leukemia - Cancer Health
-
'Game-changer' cancer drug celebrates 20 years. Gleevec turned a death sentence into a chronic disease for many. - USA Today
-
Takeda's Iclusig delivers a win in rare subtype of acute lymphoblastic leukemia - Fierce Pharma
-
Study finds generic options offer limited savings for expensive drugs - Vanderbilt Health News
-
FDA Approves New Imatinib (Imkeldi) Formulation for Various Cancer Types - Oncology News Central
-
Miracle drug with Israeli roots saves Jewish hockey player hit with cancer - The Times of Israel
-
Cancer drug may help patients with severe asthma - WashU Medicine
-
Iclusig With Chemo ‘Should Be Standard of Care’ for ALL Subset - Cure Today
-
Dr. Reddy's plant problems may derail launch of generic Gleevec - Fierce Pharma
-
Modest Price Cut Expected For Generic Version Of Cancer Pill Gleevec - WUNC News
-
Clinical trial results show promise for drug targeting rare stomach cancer - OHSU News
-
This drug is defying a rare form of leukemia — and it keeps getting pricier - The Washington Post
-
Novartis agrees Gleevec patent deal - Pharmafile
-
Gastrointestinal Stromal Tumors Already Proving to Be Treatable With Targeted Therapies - Cure Today
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.